Sativex long-term use: an open-label trial in patients with spasticity due to MS
Summary: This new study from a research group in Scotland assesses the long term safety profile of regular Sativex use for spasticity in MS.
The report, which follows-up 146 patients using treatment for a mean duration of 334 days, administering a mean of 7.3 actuations per day, found that 36% withdrew in the first year, either due to adverse events of lack of efficacy. Most common adverse events were fatigue and dizziness. Serious adverse events were rare and included two psychiatric events in the same patient. No serious effects were seen with abrupt withdrawal and patients did not build up a tolerance to the drug in this study....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814